Abstract

Developing an Erythromycin Ophthalmic Ointment: Putting the Puzzle Pieces Together

Author(s): McElhiney Linda F

Issue: Jul/Aug 2010 - Sterile Compounding

Page(s): 270-274

Download in electronic PDF format for $75

Abstract

With the development of new treatment options and reported side effects with the use of silver nitrate ophthalmic solution, the drug manufacturers discontinued production of the silver nitrate ophthalmic solution in the mid 1990s. On December 9, 2009, the U.S. Food and Drug Administration announced that the erythromycin ophthalmic ointment 1-gram tubes were commercially available again and production by the manufacturer was expected to meet the historical demands. Hospitals could expect to replenish their inventory reserves after the first quarter of 2010. However, manufacturer backorders have been increasing due to a variety of factors. If a hospital has a compounding laboratory, it is possible to prepare erythromycin ophthalmic ointment according to the United States Pharmacopeia Chapter <797> standards. Since the commercial product has been available for decades without any major shortages until 2009, there isn’t any published compounding information on how to prepare the ointment. This article discusses t

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
Jul/Aug 2010 Pg. 270-274	Developing an Erythromycin Ophthalmic Ointment: Putting the Puzzle Pieces Together Author(s): McElhiney Linda F
Jan/Feb 2003 Pg. 10-15 View Sample	Compounding for the Effects of Weapons of Mass Destruction Author(s): Sammarco Domenic A
Mar/Apr 2008 Pg. 153	Erythromycin 1% and Neomycin Sulfate Ointment Author(s): Allen Loyd V Jr
Nov/Dec 2016 Pg. 495-500	Basics of Sterile Compounding: Ophthalmic Preparations, Part 2: Suspensions and Ointments Author(s): Allen Loyd V Jr
May/Jun 2016 Pg. 228	Dexamethasone 0.1%, Neomycin 0.35%, and Polymixin 10,000 Units/g Ophthalmic Ointment Author(s): Allen Loyd V Jr
Jan/Feb 2015 Pg. 64	Erythromycin 50-mg/mL Injection Author(s): Allen Loyd V Jr
Jan/Feb 2016 Pg. 51	Dexamethasone, Neomycin, and Polymyxin Ophthalmic Ointment Author(s): Allen Loyd V Jr
May/Jun 2001 Pg. 212	Tetracycline HCl 1% Ophthalmic Ointment Author(s): Allen Loyd V Jr
Nov/Dec 2002 Pg. 452	Erythromycin and Dexamethasone Ophthalmic Solution Author(s): Allen Loyd V Jr
May/Jun 2003 Pg. 215	Dexamethasone Phosphate 0.05% Ophthalmic Ointment Author(s): Allen Loyd V Jr
Nov/Dec 2003 Pg. 467	Bacitracin 500-U/g Ophthalmic Ointment Author(s): Allen Loyd V Jr
Sep/Oct 2010 Pg. 421	Three Fortified Ophthalmic Solutions: Amikacin 5% Ophthalmic Solution; Ceftazidime 5% Ophthalmic Solution; Vancomycin 5% Ophthalmic Solution Author(s): Allen Loyd V Jr
Jul/Aug 2003 Pg. 266-270	Sensitization Therapy for Warts Author(s): Kuntz Rachael
Jul/Aug 2003 Pg. 288-291	Basics of Compounding for Raynaud's Disease Author(s): Glasnapp Andrew
Mar/Apr 2001 Pg. 145-146	Ointment Vehicles, Featured Excipient: Author(s): Allen Loyd V Jr
May/Jun 1998 Pg. 230	Glucose 40% Ophthalmic Ointment Author(s): Allen Loyd V Jr
Sep/Oct 2003 Pg. 373	Chloramphenicol 1% Topical Ointment Author(s): Allen Loyd V Jr
Sep/Oct 2016 Pg. 399-404	Basics of Sterile Compounding: Ophthalmic Preparations, Part 1: Ophthalmic Solutions Author(s): Allen Loyd V Jr
Jan/Feb 2025 Pg. 51	Three Fortified Ophthalmic Solutions: Amikacin 5% Ophthalmic Solution; Ceftazidime 5% Ophthalmic Solution; Vancomycin 5% Ophthalmic Solution Author(s):
Jul/Aug 2021 Pg. 344-351	Stability of Compounded Topical Nifedipine in Cream, Gel, and Ointment Bases Author(s): Teimouri Arezou, Yeung Pollen, Agu Remigius U